NCT05066945Not yet recruiting
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Application of Circulating Tumor (ctDNA) in the Evaluation of Curative Effect and Prognosis of Small Cell Lung Cancer (SCLC) Patients
Source: ClinicalTrials.gov · Last updated 4 Oct 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and chemotherapy treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 19 Aug 2021
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Lung cancer
- NCT number
- NCT05066945
What you commit to
- Study type: Observational
- Planned participants: 40
- From 1 Jan 2022 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients have other primary cancers;
Other
- Patients unable to cooperate with the study for follow-up according to the determined clinical follow-up cycle;
- Unable to accept the judgment of curative effect evaluation by the designated methods such as CT.
Who the study is looking for
- Provision of informed consent；
- Newly diagnosed and histological or cytological confirmed extensive stage small cell lung cancer;
- All indicators has confirmed and allow to receive radiotherapy and chemotherapy;
- Follow-up can be carried out and the peripheral blood samples can be collected;
- Cooperate with the provision of clinical pathological data required by the research.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.